Mark Elliott Boulding - Apr 5, 2022 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
EXEC. VP AND CLO
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Stock symbol
PTCT
Transactions as of
Apr 5, 2022
Transactions value $
-$225
Form type
4
Date filed
4/7/2022, 04:03 PM
Previous filing
Feb 11, 2022
Next filing
Apr 15, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Options Exercise $56.20 +5 +0.01% $11.23 61.1K Apr 5, 2022 Direct F1
transaction PTCT Common Stock Sale -$225 -5 -0.01% $45.00 61.1K Apr 5, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Options Exercise -$56 -5 -0.22% $11.23 2.28K Apr 5, 2022 Common Stock 5 $11.23 Direct F1, F2
holding PTCT Stock Option (Right to Buy) 85.6K Apr 5, 2022 Common Stock 85.6K $51.00 Direct F2
holding PTCT Stock Option (Right to Buy) 70K Apr 5, 2022 Common Stock 70K $30.86 Direct F2
holding PTCT Stock Option (Right to Buy) 72.5K Apr 5, 2022 Common Stock 72.5K $33.02 Direct F3
holding PTCT Stock Option (Right to Buy) 17.5K Apr 5, 2022 Common Stock 17.5K $33.02 Direct F4
holding PTCT Stock Option (Right to Buy) 59.5K Apr 5, 2022 Common Stock 59.5K $51.16 Direct F5
holding PTCT Stock Option (Right to Buy) 59.5K Apr 5, 2022 Common Stock 59.5K $66.49 Direct F6
holding PTCT Stock Option (Right to Buy) 54K Apr 5, 2022 Common Stock 54K $38.10 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the reporting person on December 2, 2021.
F2 Currently exercisable.
F3 This option was granted on January 22, 2019 and vests over four years, with 25% of the shares underlying the option vesting on January 22, 2020, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning April 22, 2020.
F4 This option was granted on January 22, 2019 and vests over four years, with 50% of the shares underlying the option vesting on January 22, 2022, and the remaining 50% of the original number of shares underlying the option vesting on January 22, 2023.
F5 This option was granted on January 29, 2020, and vests over four years, with 25% of the shares underlying the option vesting on January 29, 2021, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 29, 2021.
F6 This option was granted on January 6, 2021, and vests over four years, with 25% of the shares underlying the option vesting on January 6, 2022, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 6, 2022.
F7 This option was granted on January 7, 2022, and vests over four years, with 25% of the shares underlying the option vesting on January 7, 2023, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 7, 2023.